RT journal article
T1 Measles Virus-Specific Antibody Levels in Individuals in Argentina Who Received a One-Dose Vaccine
A1 Argüelles, Marcelo H.
A1 Orellana, Mariana L.
A1 Castello, Alejandro A.
A1 Villegas, Guillerno A.
A1 Masini, Matilde
A1 Belizan, Alejandra L.
A1 Gonzalez Ayala, Silvia
A1 Vera, Osmar Darío
A1 Glikman, Graciela
A2 Didáctica
AB In spite of active measles virus (MV) vaccination strategies, reemergence continues to occur, impairingglobal eradication programs. The immune status against measles was evaluated in 350 vaccinated healthyArgentine children and teenagers who received a single dose of the MV Schwarz strain Lirugen vaccine (AventisPasteur). Sera were assessed for immunoglobulin G (IgG) antibodies by a commercial enzyme immunoassay(EIA) (Enzygnost; Behring), an in-house EIA, and neutralization EIA. Results obtained with these methodsshowed a marked decline in IgG level with increasing age. At 1 to 4 years of age, 84% of children had IgGantibodies above 200 mIU/ml, conventionally accepted as protective levels, whereas only 32% of older childrenand teenagers had antibody levels exceeding 200 mIU/ml. Moreover, the MV IgG content in the teenage groupwas significantly lower than the IgG antibody level of the group of younger children (P < 0.0001). In contrast,screening for IgG antibody levels to inactivated tetanus vaccine showed that, on average, 80% of this populationwas fully protected and that this high level of protection remained through the teenage years. This studysuggests that within this population a considerable proportion of individuals had low measles antibody levelsthat may be insufficient to protect against reinfections or clinical disease.
PB American Society for Microbiology
SN 0095-1137
YR 2006
FD 2006-06-08
LK http://hdl.handle.net/10498/36391
UL http://hdl.handle.net/10498/36391
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 11-nov-2026